Amplify Weight Loss Drug & Treatment ETF Rating $21.22 +0.10 (+0.47%) As of 04/25/2025 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartHoldingsOwnershipRatingsBuy This Stock Amplify Weight Loss Drug & Treatment ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.THNR Aggregate RatingModerate Buy 2.67Holdings in THNR have an aggregate rating of Moderate Buy based on 186 analyst ratings issued in the past year covering 14 companies (70.6% of the portfolio).THNR Aggregate Price Target$21.22High Prediction$21.22Average Prediction$21.22Low Prediction$21.22Holdings in THNR have an aggregate price target of $21.22 and a range of $21.22 to $21.22 covering 14 companies (70.6% of the portfolio).THNR Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy3 Buy rating(s)Moderate Buy8 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Amplify Weight Loss Drug & Treatment ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 14 THNR Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings15.38%LLYEli Lilly and Company$884.94+2.9%4.8241 of 5 stars2.89$1,017.00 14.9%19Upcoming EarningsAnalyst ForecastAnalyst RevisionPositive News13.89%NVONovo Nordisk A/S$62.07-0.9%4.5061 of 5 stars2.25$135.00 117.5%12Analyst UpgradeGap Down5.23%WSTWest Pharmaceutical Services$214.56+1.9%4.6905 of 5 stars3.00$332.50 55.0%8Earnings ReportDividend AnnouncementNews Coverage5.05%AMGNAmgen$280.84+0.4%4.6524 of 5 stars2.43$310.57 10.6%23Upcoming EarningsAnalyst ForecastAnalyst RevisionPositive News4.90%AZNAstraZeneca$69.57+0.0%3.7263 of 5 stars3.10$88.00 26.5%10Upcoming EarningsAnalyst RevisionNews CoveragePositive News4.84%TMOThermo Fisher Scientific$424.02-0.6%4.9349 of 5 stars2.81$616.95 45.5%21Earnings ReportAnalyst ForecastAnalyst RevisionPositive News4.81%PFEPfizer$22.95+0.7%4.9993 of 5 stars2.53$29.57 28.9%17Upcoming EarningsDividend AnnouncementAnalyst ForecastAnalyst Revision4.56%TEVATeva Pharmaceutical Industries$14.88+1.1%3.1254 of 5 stars2.86$23.43 57.5%7Analyst UpgradePositive News4.51%MRKMerck & Co., Inc.$82.83+3.7%5 of 5 stars2.59$111.13 34.2%22Earnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionPositive NewsHigh Trading Volume3.70%HIMSHims & Hers Health$28.10-0.1%3.8664 of 5 stars2.15$38.08 35.5%13Analyst ForecastInsider Trade1.78%GPCRStructure Therapeutics$23.74+0.4%2.4637 of 5 stars3.00$81.29 242.4%8Analyst ForecastNews Coverage1.51%VKTXViking Therapeutics$24.99-2.6%4.2102 of 5 stars2.92$89.50 258.1%13Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap Down0.26%OPKOPKO Health$1.41-3.4%3.9766 of 5 stars2.75$2.75 95.0%4Upcoming EarningsAnalyst ForecastNews CoveragePositive News0.20%ALTAltimmune$5.07-1.9%2.5318 of 5 stars2.89$20.83 310.9%9 This page (NYSEARCA:THNR) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amplify Weight Loss Drug & Treatment ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Amplify Weight Loss Drug & Treatment ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy THNR Stock Free THNR Stock Alerts